Immunotherapy improves survival in metastatic or recurrent head and neck cancer

(European Society for Medical Oncology) Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news